Status:
COMPLETED
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma
Lead Sponsor:
Roswell Park Cancer Institute
Conditions:
Plasma Cell Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This trial studies how well strength training works in improving bone health, pain, and quality of life in patients with multiple myeloma. Weekly physical activity may improve bone recovery, reduce pa...
Detailed Description
PRIMARY OBJECTIVES: * I. To assess the feasibility of a 6 month, twice weekly supervised strength training intervention in patients with multiple myeloma. (Cohort 1) * II. To assess the feasibility o...
Eligibility Criteria
Inclusion
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
- Have a diagnosis of multiple myeloma
- Show no signs of comorbidities, myeloma symptoms, or treatment side effects that would put them in danger when participating in the study according to the physician's discretion
- Are able to understand and follow assessment and training procedures
- Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion
- Current and symptomatic pathological fracture(s) or severely advanced instability of the musculo-skeletal system
- Acute bone instability as assessed by whole body low-dose computed tomography and evaluated by an experienced neuro- and spine surgeon
- Major comorbidities that would cause danger to the patient when participating in the study. Examples are cardiac or pulmonary and infectious diseases that would have a risk of progression if the patient took part in the study
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate to take part in study intervention (comorbidities, myeloma symptoms, treatment side effects)
Key Trial Info
Start Date :
December 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2022
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT03793907
Start Date
December 17 2019
End Date
November 10 2022
Last Update
April 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263